Regulation of T Cell Homeostasis and Responses by Pten

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th>Citation</th>
<th>Newton, Ryan H., and Laurence A. Turka. 2012. Regulation of T cell homeostasis and responses by Pten. Frontiers in Immunology 3:151.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.3389/fimmu.2012.00151</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:10436289">http://nrs.harvard.edu/urn-3:HUL.InstRepos:10436289</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
INTRODUCTION

Class I A PI3Ks are directly linked to lymphocyte activation mainly through receptor tyrosine kinases, such as the antigen and cytokine receptors (Engelman et al., 2006; Huang and Sauer, 2010; So and Fruman, 2012). Class I A PI3Ks, hereafter referred to as PI3K, are comprised of a catalytic subunit of 110 kDa (of which there are three isoforms) that generates phosphatidylinositol 3,4,5 phosphate (PIP3) from its main substrate phosphatidylinositol 4,5 phosphate (PIP2), and a regulatory subunit (of which there are five isoforms). Pten encodes a protein with a lipid phosphatase function that directly opposes PI3K signaling by dephosphorylating PIP3 at the 3′ position to generate PIP2. Cells lacking PTEN have elevated levels of PIP3 and constitutive activation of PI3K signaling pathways (Stambolic et al., 1998; Cantley and Neel, 1999). With increasing age, mice heterozygous for Pten develop T cell lymphomas and cancers in multiple tissues, and develop a lethal polyclonal autoimmune disorder, similar to that seen in Fas−/− mice (Di Cristofano et al., 1998, 1999; Podsypanina et al., 1999, Suzuki et al., 2001). Germ-line mutations in PTEN occur in a group of autosomal dominant syndromes known as the PTEN hamartoma tumor syndromes, which include Cowden syndrome, Proteus syndrome, Proteus-like syndrome, and Banayan–Ruschalka syndrome, demonstrating the importance of PTEN as a tumor suppressor. Consistent with this, genomic amplification and mutation of either PI3K or Akt has been reported in a large number of cancers as well (Samuels et al., 2004; Lee et al., 2005; Carpenter et al., 2007; Eads et al., 2009), although the role of PTEN as a tumor suppressor is now believed to involve more than its ability to oppose PI3K signaling. While disruption of regulation of T cells from these mice also able to proliferate under co-stimulatory conditions in the absence of detectable Akt signaling. These mice also maintain a normal anti-viral response upon MHV infection, although in vivo T helper function to B cell antibody responses was impaired. Whether the relative lack of defects is due to the fact that lack of PI3K was genetic, rather than acquired, is not known. However, these studies indicate that potential therapies targeting PI3K for inflammatory diseases and cancer may not compromise all aspects of cellular immunity, and further suggest that PI3K signaling has specialized functions in the context of T cell activation.

ACTIVATION AND REGULATION OF PI3K CLASS 1A IN T LYMPHOCYTES

Upon ligation of the T cell receptor (TCR) in the presence of co-stimulatory molecules, PI3K recruitment and activation leads to the production of lipid products which in turn recruit downstream PI3K-pathway, controlling cell growth and metabolism. Members of the Foxo family of transcription factors are also regulated by Akt, thus linking control over homing and migration of T cells, as well as cell cycle entry, apoptosis, and DNA damage and oxidative stress responses, to PI3K signaling. PTEN, first identified as a tumor suppressor gene, encodes a lipid phosphatase that, by catalyzing the reverse of the PI3K "reaction," directly opposes PI3K signaling. However, PTEN may have other functions as well, and recent reports have suggested roles for PTEN as a tumor suppressor independent of its effects on PI3K signaling. Through the use of models in which Pten is deleted specifically in T cells, it is becoming increasingly clear that control over autoimmunity and lymphomagenesis by PTEN involves multi-faceted functions of this molecule at multiple stages within the T cell compartment.

Keywords: Pten, T cells, autoimmunity, lymphoma
PTEN function in T cells

Class IA PI3Ks are activated by receptor tyrosine kinases that drive co-stimulatory, T cell receptor (TCR), and cytokine signaling pathways. PTEN directly opposes PI3K signaling by converting PI(3,4,5)P3 to PI(4,5)P2. Through their PH-domains, PDK1 and Akt bind PIP3, enabling Akt to be phosphorylated by PDK1 on Ser308. Full activation of Akt requires phosphorylation on Ser473 by mTORC2. Akt can then target downstream substrates such as Foxo in the nucleus, leading to their inactivation and export from the nucleus. This results in attenuation of a Foxo-dependent gene program normally acting to promote pathways involved in, but not limited to, T cell homeostasis (in resting T cells), apoptosis (upon, for example, cytokine withdrawal), Treg induction, and homing to secondary lymphoid organs (in circulating, naive T cells). Akt also targets TSC2 and Pras40 (not shown), negative regulators of mTORC1, allowing for activation of mTORC1. Activation of S6K and 4EBPs by mTORC1 results in increased protein translation, allowing growth and proliferation, and upregulation of Hif-1α, important for glycolytic metabolism. Inhibitory targeting of Bad and GSK3 also contribute to Akt's effect on cell cycle, survival and metabolism.

Engagement of the IL-2R on activated T cells results in activation of the Jak/Stat pathway, as well as the PI3K and MAPK pathways, and the combination of these signals is required for the observed proliferation and cell survival in response to IL-2. Thus, appropriate responses to TCR ligation and cytokines require downregulation of PTEN, which is constitutively expressed in naïve T cells. This normally occurs as a consequence of TCR stimulation itself, which terminates detectable PTEN expression within 24–48 h. The importance of this is demonstrated by two findings. First, retroviral mediated "enforced" expression of PTEN renders activated IL-2R⁺ T cells unable to fully respond to IL-2 stimulation. Second, regulatory T cells, which normally do not divide in response to IL-2 alone, have complete responses and signaling to IL-2 restored solely by genetic ablation of Pten (Bensinger et al., 2004; Walsh et al., 2006; Locke et al., 2009). This demonstrates that control of PI3K through PTEN plays an important role not only in modulating the degree of activation signals within lymphocytes, but in maintaining traits of a specific lineage.

PI3K-related signals can modulate ongoing responses as well. Deletion of Pten, or expression of constitutively active myristoylated-Akt, within the CD8⁺ T cell compartment inhibits the development and survival of memory CD8⁺ T cells (Hand et al., 2010). On the contrary, Akt is required for a transcriptional program leading to upregulation of cytolytic effector, chemokine, and adhesion molecules (Macintyre et al., 2011). Conditional deletion of Pten using OX40-Cre has demonstrated that PTEN plays a critical role in limiting the expansion of Th1 cells and in maintaining control over GC reactions, indicating that T cell intrinsic roles of PTEN are crucial for maintaining global levels of tolerance (Rolf et al., 2010). Lastly, the promotion of iTreg generation and maintenance by PD-L1 is associated with down-regulation of Akt signaling and concomitant upregulation of PTEN expression (Francisco et al., 2009). These examples all provide evidence that the balance of Akt signaling within multiple stages of development and differentiation states helps determine cellular fate.

PTEN also has been shown to play an important role in central tolerance and in regulating proliferation of developing cells in the thymus (Suzuki et al., 2001; Hagenbeck et al., 2004). In the absence of IL-7R and pre-TCR signaling, loss of Pten allows cells to bypass the β-selection checkpoint, indicating that PI3K signaling is crucial...
for the ongoing development of early T cell precursors. Interestingly, thymic cellularity and subset percentages are relatively unperturbed prior to tumor development, which likely occurs at the DP stage during thymic maturation, suggesting that secondary events emerge in this context of Pten loss to promote transformation (discussed below; Hagenbeek et al., 2004; Hagenbeek and Spits, 2008; Xu et al., 2008; Guo et al., 2011).

**SIGNALLING DOWNSTREAM OF Pten-PI3K-Akt: A CRITICAL ROLE FOR FOXOS**

Members of the Foxo family of transcription factors play a critical role in DNA damage and oxidative stress responses (Tran et al., 2002; Miyamoto et al., 2007; Tothova et al., 2007; Choi et al., 2009) and in preventing entry into cell cycle (Modena et al., 2000), acting as bona fide tumor suppressors as demonstrated in hematopoietic and epithelial tissues (Coffer, 2003; Accili and Arden, 2004; Paik et al., 2007). It is becoming increasingly appreciated that Foxos play important roles within the T cell compartment as well, regulating homing (Fabre et al., 2008; Sinclair et al., 2008; Finlay et al., 2009; Keräldes et al., 2009; Finlay and Cantrell, 2010), survival (Hedrick, 2008; Keräldes et al., 2009; Dejaz et al., 2011), and the development and function of effector and memory subsets (Keräldes et al., 2010; Ouyang et al., 2010; Rao et al., 2012). In quiescent cells, Foxos are active within the nucleus, where they maintain the pattern of chemokine and adhesion molecule expression, and expression of the IL-7R, needed for the migration and survival of circulating T cells (Fabre et al., 2008; Finlay et al., 2009; Keräldes et al., 2010). Akt phosphorylation on Ser473, mediated by mTORC2, is critical for Foxo inactivation, implicating mTOR in control over Foxos, and placing PTEN upstream of Sirt1. Akt phosphorylation on Ser473, mediated by mTORC2, is critical for Foxo inactivation, implicating mTOR in control over Foxos, and placing PTEN upstream of Sirt1.

**LYMPHOMA AND DYSREGULATED IMMUNE FUNCTION IN THE ABSENCE OF Pten**

Genetic studies in mice expressing conditional alleles of Pten have been crucial for studying the tissue specific role of Pten in tumorigenesis. Deletion of Pten in hematopoietic cells using Mx-1-Cre results in myeloproliferative disease and transplantable leukemia, and has shown that Pten is required for maintaining the hematopoietic stem cell (HSC) compartment (Yilmaz et al., 2006; Lee et al., 2010). Similar to the Mx-1-Cre model of PTEN loss, Vec-Cre-mediated PTEN loss, in which nearly 40% of fetal liver HSCs were subject to deletion of Pten, led to impaired HSC self-renewal and the development of a myeloproliferative disorder followed by leukemia (Guo et al., 2008). It is notable that this phenotype shares striking similarity to mice in which all six alleles of Foxo3a/4 were deleted by Mx-1-Cre (Tothova et al., 2007), and to Foxo3a−/− mice (Miyamoto et al., 2007). Importantly, this study reported the same t(14;15) chromosomal translocation (seen within a subset of human T-ALL), in all blast-crisis samples analyzed from these mice, suggesting a critical genomic destabilizing event potentially independent of Pten’s role in controlling PI3K/Akt signaling. Similarly, this translocation, involving the c-myc and TcR β loci and resulting in constitutively high levels of c-myc, was found to recur with 100% incidence in T cell lymphomas from mice in which Pten was deleted specifically.
Akt directly repress multiple target genes of c-myc and block onco-"fimmu-03-00151" — 2012/6/13 — page 4 — #4
tic development, although lymphomagenesis developed with delayed onset and was primarily restricted to the thymus (Liu et al., 2010). Interestingly, mature T cells from 3-week-old PTEN−/− mice that had not undergone transformation, when transferred into either immunocompetent or immunocompetent recipients, did not develop a malignant phenotype throughout the duration of the host’s life, suggesting that malignancy arises within the thymus after a period of latency in these mice, consistent with an earlier report demonstrating that transplanted PTEN−/− thymocytes gave rise to T cell lymphomas in immunocompetent recipients (Hagenbeek and Spits, 2008). Supporting this, PTEN−/− mice thymectomized at 3 weeks of age did not develop lymphomas, although later in life these mice exhibited signs of systemic autoimmunity. Thus, within distinct developmental stages, PTEN is required for the prevention of lymphoma and autoimmunity.

In the context of DNA damage, loss of PTEN enables cells to bypass the normal G2/M checkpoint enforced by CHK1 as a result of Akt-mediated CHK1 sequestration in the cytoplasm (Puc et al., 2008). Akt has also been shown to promote prosurvival responses following DNA double-strand breaks (DSBs; Bozulic et al., 2008). It is possible that secondary mutations or other genetic alterations following DNA double-strand breaks (DSBs; Bozulic et al., 2008) could be prevented by a phosphatase-dead PTEN protein which retained its ability to bind to CENP-C (Shen et al., 2007). Additionally, nuclear exclusion of PTEN, but not a phosphatase-inactive mutant, was shown to impair the tumor-suppressive APC-CDH1 nuclear complex, again demonstrating tumor-suppressible capability of catalytically inactive PTEN (Song et al., 2011). Additional protein–protein interactions within the nucleus, independent of PTEN catalytic activity, have been shown to increase the activity and stability of p53 (Li et al., 2006; Salmena et al., 2008), and upregulate expression of Rad51, an essential component of the DSB repair machinery (Baker, 2007; Shen et al., 2007). A lysine to glutamate mutation in PTEN (K298E) identified in a Cowden syndrome family, which lead to a dramatic decrease in nuclear import without disrupting phosphatase activity or membrane localization of PTEN, as well strongly supports the idea that nuclear PTEN can be critical for tumor suppression independent of its role in opposing PI3K signaling in certain contexts (Trotman et al., 2007).

Inactivation of PTEN phosphatase activity is sufficient to abrogate its tumor-suppressive effects, emphasizing the importance of PTEN’s role in downregulation of PI3K signaling. This has been demonstrated by a subset of Cowden disease patients that harbor a missense mutation at a cysteine residue (C124) critical for phosphatase activity. A C124S mutant has been shown to form a stable complex with PIP3, potentially protecting it from dephosphorylation by other lipid phosphatases to account for higher cellular levels of PIP3 compared to conditions in which PTEN is completely absent (Myers et al., 1998). As well, the importance of Akt activity in tumor development induced by loss of PTEN has been reported in a number of studies (Stiles et al., 2002;
FIGURE 2 | Molecular and phenotypic consequences of loss of PTEN phosphatase-dependent and -independent functions during hematopoiesis and within the T cell compartment. Loss of PTEN phosphatase activity results in increased levels of PIP3, causing hyperactivation of the Akt pathway and subsequent activation of the mTOR pathway, and inactivation of the Foxo family of transcription factors. Disruption of PTEN phosphatase-independent function accounts for loss of much of its nuclear activity, compromising genetic stability and DSB repair, leading to chromatid breaks and translocations. That mature T cells do not undergo transformation, and that lymphoma in T cell-specific PTEN knockout mice is of thymic origin, suggests that PTEN phosphatase-independent function contributes less to the phenotype at the mature T cell stage, and that loss of T cell tolerance can likely be attributed to loss of PTEN phosphatase activity. Whether depletion of hematopoietic stem cells (HSCs) and development of leukemia stem cells (LSCs), as well lymphomagenesis, depends on the absence of PTEN phosphatase activity (which likely maintains survival of genetically aberrant cells), PTEN phosphatase-independent activity (promoting genetic instability), or both, remains an open question.

Bayascas et al., 2005; Chen et al., 2006). Constitutive Akt activation in T cells and thymocytes has been shown to be sufficient to drive autoimmune and lymphoma (Rathmell et al., 2003) and bone marrow chimera experiments have demonstrated that enforced expression of constitutively active Akt in HSCs was sufficient for the development of myeloproliferative disease, T cell lymphoma, or AML (Kharas et al., 2010).

PTEN−/−ΔT mice crossed onto the R26Ai cre activity background, which do not harbor the t(14;15) translocation, potentially serve as an example in which Akt signaling is not sufficient to drive cancer progression (Liu et al., 2010). In vitro studies using malignant cells from these mice demonstrated a dependence on Notch, suggesting that Akt at the very least must cooperate with other oncogenic pathways to allow tumor growth in this model, similar to what has been suggested in an MMTV-myAkt breast cancer model with respect to tumorigenesis induced by loss of PTEN (Blanco-Aparicio et al., 2007). In contrast to this, in a model of Notch-induced tumorigenesis, genetic loss of Pten induced an oncogene addiction switch that rendered T-ALL cells resistant to Notch inhibition through GSIs and dependent on PI3K/Akt signaling to maintain tumor growth (Palomero et al., 2007). Thus, the reliance on Akt signaling differs among models of PTEN loss. This idea is perhaps emphasized by the observation that PTEN−/−ΔT mice, regardless of whether the t(14;15) translocation event occurs, maintain constitutively high levels of c-myc.

The reliance on c-myc in the context of PTEN loss remains an important question. In tumors driven by inducible c-myc activation in a zebrafish model of T-ALL, constitutive activation of the Akt pathway through genetic disruption of Pten or transgenic
expression of Akt1 rendered cells in this model independent of c-myc for tumor progression (Gatiueres et al., 2011). Conversely, conditional genetic disruption of both Pten and c-myc in mice, while still subject to myeloproliferative and lymphoproliferative nancies, highlighting an important dependence on c-myc in this context of PTEN loss (Zhang et al., 2011). Whether loss of PTEN allows the survival of cells that, through other mechanisms, have c-myc, independent of its role in PFKD downregulation, prevents genetic instability that collaborates with dysregulation of PFKD to allow cancer progression, remains an open question that needs to be addressed in a context-dependent manner, with consideration of what function of PTEN is lost, changes in levels of expression, and in which tissues abnormal growthFortunately.

PTEN is the one of the most frequently mutated or lost genes in human cancer. Given the emerging roles of PI3K in immune system regulation, it is possible that PTEN is also playing a prominent role in the prevention of autoimmune disease and inflammatory/lymphoproliferative syndromes. The finding that PTEN did not play a role in lymphomagenesis in mature T cells from mice which lack PTEN specifically in T cells suggested that PTEN has a specific function in preventing lymphoma within a distinct time frame in this compartment. That these non-malignant T cells were able to provoke autoimmunity demonstrates that well beyond the stage at which PtEN is required for prevention of lymphomagenesis in this model, PTEN plays a critical role in the maintenance of T cell tolerance. It will be important to determine which biochemical requirements PTEN fulfills in each stage of protection, and whether these requirements are distinct within different stages from cells of the same lineage, or whether lack of particular features leads to different outcomes depending on developmental stage. Given the importance of PTEN signaling in both normal immunity and the development of cancer, it will be interesting to see how closely PTEN’s role as a lipid phosphatase is tied to prevention of disease, and how integral PFKD signaling remains throughout disease progression. Uncovering the specific biochemical functions of PTEN within these contexts will be key to the development of targeted therapies for the prevention and treatment of T cell malignancies and autoimmune disease.

REFERENCES


the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 208, 3015–3029.


Palermo, T., Suki, M. L., Cortina, M., Reid, P. J., Barnes, K., Cio


Pau, J., Kenderi, M. L., Li, S. H., Panda, T. K., Choudhury, A. D., Momo, N., Manoahin, M., Murty, V. V., Gagin, Z., Mark, S. E., Pena

can, Z., Shrikant, P. A. (2012). Transcrip


like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p70S6K. Nature 404, 782–787.


agenesis and deplete hematopoietic stem cells after Pan deletion. Cell Stem Cell 6, 303–315.


Liu, X., Karr, K., Jin, Y., Zhang, R., Zhang, J., Li, P., Chen, X., Miehm


like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p70S6K. Nature 404, 782–787.


agenesis and deplete hematopoietic stem cells after Pan deletion. Cell Stem Cell 6, 303–315.


Liu, X., Karr, K., Jin, Y., Zhang, R., Zhang, J., Li, P., Chen, X., Miehm


Frontiers in Immunology | T Cell Biology

June 2012 | Volume 3 | Article 151 | 5


T-cell development and therapeutic advances. Biochem. J. 442, 469–481.


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

This article was submitted to Frontiers in Immunology. Copyright © 2012 Newton and Turka. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

This article was submitted to Frontiers in T Cell Biology, a specialty of Frontiers in Immunology. Copyright © 2012 Newton and Turka. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.

“fimmu-03-00151” — 2012/6/13 — 21:07 — page 8 — #8